Where to Buy Research-Grade MOTS-c, 5-Amino-1MQ, and GLP-3 Retatrutide Together: Vendor Selection for Advanced Metabolic Stacks

Only one of the three compounds in this stack can actually be purchased today, and knowing which one cannot be sourced from any vendor is the most important piece of information a research lab can have before spending time on procurement.

The question of where to buy research-grade MOTS-c, 5-Amino-1MQ, and GLP-3 Retatrutide together for advanced metabolic stacks is asked frequently in 2026, but the honest answer is more nuanced than a vendor list. Two of these compounds have active research-chemical marketplaces. The third, retatrutide, is a proprietary investigational drug owned by Eli Lilly, accessible only inside formal clinical trials, and cannot be legally sold or marketed by any third-party supplier.

This guide breaks down each compound's sourcing reality, the vendor criteria that matter most, and how to build the strongest possible metabolic research stack within legal and regulatory boundaries.

Key Takeaways

• MOTS-c is available from multiple vetted peptide vendors as a lyophilized research compound; prioritize lot-matched COAs, LC-MS identity testing, and USP endotoxin screening.
• 5-Amino-1MQ is a small-molecule NNMT inhibitor classified as Research Use Only (RUO); it is not a peptide, and several reputable chemical suppliers offer it in research-grade vials.
• Retatrutide (LY3437943) is an investigational triple hormone receptor agonist that cannot be legally purchased from any retail or research-chemical source in 2026.
• When sourcing multiple compounds for a metabolic stack, vendor transparency, third-party testing, and RUO labeling are the non-negotiable baseline criteria.
• The practical "advanced metabolic stack" available to researchers today pairs MOTS-c with 5-Amino-1MQ; retatrutide remains a future consideration pending potential regulatory approval.

Understanding the Three Compounds Before Sourcing Them

Before evaluating any vendor, researchers need a clear picture of what each compound is, and what category it falls into.

MOTS-c is a 16-amino-acid mitochondrial-derived peptide. It is synthesized via solid-phase peptide synthesis, supplied as a lyophilized powder, and framed as a research compound for in vitro and laboratory use. For a deeper look at how this peptide fits into cellular energy research, the article on mitochondria, adenosine triphosphate, and peptide signaling where MOTS-c and 5-Amino-1MQ fit in cellular energy research provides useful mechanistic context.

5-Amino-1MQ is a small-molecule quinolinium heteroaromatic compound, not a peptide. It contains no amino acids and no peptide bonds. It acts as an NNMT (nicotinamide N-methyltransferase) inhibitor and is classified strictly as a Research Use Only laboratory reagent. Mislabeling it as a peptide is common among vendors; this is a red flag. For mechanism detail, see the resource on 5-Amino-1MQ peptide mechanism, metabolic research, and how it differs from mitochondrial peptides.

Retatrutide (also referred to as GLP-3 in some search contexts) is Eli Lilly's investigational triple hormone receptor agonist, activating GIP, GLP-1, and glucagon receptors simultaneously. As of 2026, Lilly's TRIUMPH Phase 3 program has reported positive topline results across obesity-related indications, but the compound remains unapproved and is classified as investigational. No authorized research-reagent distribution channel exists. For more on how it differs from other GLP-class compounds, see what is GLP-3 peptide and how researchers distinguish it from retatrutide in search intent and lab context.

Critical point: Any vendor claiming to sell retatrutide as a research chemical or metabolic stack component in 2026 is not operating within a legitimate regulatory framework. There is no lawful third-party supply channel.

Vendor Selection Criteria for Research-Grade MOTS-c and 5-Amino-1MQ

For the two compounds that can be legitimately sourced, the quality gap between vendors is significant. The following criteria should drive every procurement decision.

Certificate of Analysis Standards

A COA is the minimum baseline, but not all COAs are equal. The strongest vendors publish lot-matched COAs, meaning the document corresponds to the exact batch being shipped, not a generic or outdated test. Key elements to verify:

• LC-MS identity confirmation, confirms the compound is what the label claims
• HPLC purity result, reputable MOTS-c suppliers consistently report purity at or above 99%
• USP less-than-85 endotoxin screening, critical for any compound used in cell-based research
• Third-party lab origin, COAs from independent labs carry more weight than in-house testing

MOTS-c Vendor Landscape in 2026

Independent vendor comparisons in 2026 identify several consistently cited sources for research-grade MOTS-c. Vendors such as Peptide Sciences, Core Peptides, and Limitless Life Nootropics are frequently noted for publishing third-party COAs, claiming purity at or above 99%, and using US-based production or fulfillment. Some comparisons rank Protide Health as a leading option based on lot-matched COA practices and endotoxin screening on every batch. The 5-Amino-1MQ and MOTS-c synergy article on how mitochondrial peptides target adiposity and insulin resistance in experimental models offers useful framing for why these two compounds are studied together.

5-Amino-1MQ Vendor Landscape in 2026

Multiple research-chemical suppliers, including Core Research Peptides, Nextday Peptides, Peptronic Labs, American Peptides, and Profound Aminos, offer 5-Amino-1MQ in small-volume vials (typically 5 mg or 50 mg). All legitimate listings frame it explicitly as an in vitro research compound with no diagnostic or therapeutic use. Researchers should verify:

• RUO labeling is present and explicit
• The compound is described as an NNMT inhibitor, not a peptide
• No health claims or human-use framing appears anywhere on the product page

For additional context on how researchers frame NAD+ and metabolic pathway questions around this compound, see 5-Amino-1MQ peptide: how researchers frame NAD+ and metabolic pathway questions.

Building the Stack: What Labs Can and Cannot Source Today

The practical metabolic research stack available in 2026 pairs MOTS-c with 5-Amino-1MQ. Retatrutide cannot be added from any retail or research-chemical source. The table below summarizes the sourcing reality.

Bundle Ordering Considerations

Most peptide vendors do not stock 5-Amino-1MQ alongside peptides, since it is a small molecule rather than a peptide. Labs should expect to source from two separate suppliers. When evaluating vendors for multi-compound orders:

• Confirm each compound ships under its own accurate regulatory framing, a vendor bundling MOTS-c and 5-Amino-1MQ while labeling both as "peptides" is demonstrating a quality-control gap.
• Check reconstitution and storage compatibility, lyophilized MOTS-c and 5-Amino-1MQ have different handling requirements. The resource on peptide calculators in research: how labs estimate dosing, concentration, and reconstitution covers practical lab preparation steps.
• Verify buyer qualification processes, vendors that require researcher verification before completing a sale signal a higher standard of compliance.

For broader context on how GLP-3-class polypeptides fit into cardiometabolic research models, the article on peptides and polypeptides in cardiometabolic research: how atorvastatin and GLP-3 retatrutide answer different questions provides useful comparative framing.

Conclusion

The search for where to buy research-grade MOTS-c, 5-Amino-1MQ, and GLP-3 Retatrutide together for advanced metabolic stacks leads to a clear, actionable answer in 2026: source MOTS-c from vendors with lot-matched COAs, LC-MS identity testing, and USP endotoxin screening; source 5-Amino-1MQ from reputable RUO chemical suppliers that correctly frame it as a small-molecule NNMT inhibitor; and recognize that retatrutide cannot be added to any stack from a third-party vendor under any legitimate procurement pathway.

Actionable next steps for research labs:

1. Audit current vendor COAs, confirm they are lot-matched and include third-party LC-MS and endotoxin data.
2. Verify that any 5-Amino-1MQ listing carries explicit RUO labeling and makes no health or peptide claims.
3. Remove retatrutide from any procurement shortlist until FDA approval and authorized distribution channels exist.
4. Monitor Lilly's regulatory submission timeline, positive Phase 3 data in 2026 suggests potential submissions in late 2026 or 2027, which could eventually open legitimate supply channels.
5. Use separate, specialized vendors for the peptide and small-molecule components of the stack, and confirm each ships with compound-specific documentation.